Matinas BioPharma Holdings, Inc.
MTNB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MTNB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MTNB
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology, with lead product candidate MAT2203 (oral amphotericin B) for antifungal indications.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Matinas BioPharma Holdings, Inc..
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology, with lead product candidate MAT2203 (oral amphotericin B) for antifungal indications.
- Matinas BioPharma is a clinical-stage biopharmaceutical company focused on its lipid nanocrystal (LNC) platform delivery technology [sec_mda · as of 2026-08-13].
- Lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug [sec_mda · as of 2026-08-13].
- Cash & equivalents were $0.8M as of 2026-06-30 [sec].
- Net income was -$1.3M for the period ended 2026-06-30 [sec].
- Shareholders' equity was $7.6M as of 2026-06-30 [sec].
What works
- The LNC platform delivery technology is a proprietary approach that could enable oral delivery of previously injectable-only drugs, potentially expanding treatment options [sec_mda · as of 2026-08-13].
- MAT2203 targets a high-need antifungal market, as amphotericin B is a potent but toxic drug that currently requires intravenous administration [sec_mda · as of 2026-08-13].
- The company is actively seeking partnerships to monetize MAT2203, which could provide non-dilutive funding and reduce financial risk [sec_mda · as of 2025-11-10].
What to weigh
- Matinas has no revenue and expects to continue incurring significant operating losses for the foreseeable future [sec_mda · as of 2026-05-08].
- Cash and cash equivalents are insufficient to fund planned operations beyond the next twelve months, raising substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-03-31].
- The company relies on external financing (equity, debt, partnerships) which may not be available on acceptable terms [sec_mda · as of 2026-03-31].
- MAT2203 is still in clinical development, and regulatory approval is uncertain and years away [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Matinas is a clinical-stage biopharmaceutical company focused on its LNC platform.
“We are a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using our lipid nanocrystal (LNC) platform delivery technology (LNC Platform).”
SEC MD&A · August 13, 2026
Lead product candidate is MAT2203 (oral amphotericin B).
“Our lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug”
SEC MD&A · August 13, 2026
Substantial doubt exists about the company's ability to continue as a going concern.
“As a result, substantial doubt exists about our ability to continue as a going concern.”
SEC MD&A · March 31, 2026
The company expects to continue incurring significant expenses and operating losses.
“We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future.”
SEC MD&A · May 8, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Cash is insufficient to fund operations beyond 12 months; substantial doubt about viability [sec_mda · as of 2026-03-31].
- No revenue and ongoing losses — No product revenue generated; expects increasing operating losses [sec_mda · as of 2026-05-08].
- Dependence on external financing — Funding through equity, debt, or partnerships may not be available on acceptable terms [sec_mda · as of 2026-03-31].
- Clinical and regulatory uncertainty — MAT2203 is still in clinical trials; regulatory approval is not guaranteed [sec_mda · as of 2026-08-13].
What to watch
- Progress of MAT2203 clinical trials and any regulatory milestones [sec_mda · as of 2026-08-13].
- Ability to secure partnership or licensing deals to monetize MAT2203 [sec_mda · as of 2025-11-10].
- Cash runway and any new financing events (equity/debt offerings) [sec_mda · as of 2026-03-31].
- Updates on the LNC platform's application to other drug candidates [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated August 18, 2026 · How we verify sources →
Run Matinas BioPharma Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Matinas BioPharma Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
1.4 months
D/E 0.90 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
27
Total value held
$182K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 80,220 | $40K |
| geode capital management, llc | 65,170 | $33K |
| citadel advisors llc | 51,698 | $26K |
| blackrock, inc. | 49,650 | $25K |
| renaissance technologies llc | 28,570 | $14K |
| xtx topco ltd | 20,706 | $10K |
| vanguard fiduciary trust co | 18,277 | $9K |
| state street corp | 15,322 | $8K |
| susquehanna international group, llp | 14,328 | $7K |
| sargent investment group, llc | 12,720 | $6K |
Showing top 10 of 27 institutional holders of Matinas BioPharma Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 0.1%
- Days to cover
- 0.1
- Shares short
- 8,751
- Daily short volume (Jul 24, 2026)
- 40.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MTNB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Matinas BioPharma Holdings, Inc.?
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology, with lead product candidate MAT2203 (oral amphotericin B) for antifungal indications.
What is Matinas BioPharma Holdings, Inc.'s lead drug candidate?
Matinas BioPharma Holdings, Inc.'s most advanced tracked candidate is mat2203 (Phase 3) for invasive aspergillosis in patients with limited treatment options.
Who is the CEO of Matinas BioPharma Holdings, Inc.?
Mr. Jerome D. Jabbour J.D. is the chief executive officer of Matinas BioPharma Holdings, Inc. (MTNB).
Where is Matinas BioPharma Holdings, Inc. headquartered?
Matinas BioPharma Holdings, Inc. (MTNB) is headquartered in Bedminster, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.